List of Excipients in Branded Drug AMANTADINE HCL

« Back to Dashboard

Generic Drugs Containing AMANTADINE HCL

Company	Ingredient	NDC	Excipient
Banner Pharmacaps Inc	amantadine hydrochloride	10888-5006	DIMETHICONE
Banner Pharmacaps Inc	amantadine hydrochloride	10888-5006	FERRIC OXIDE YELLOW
Banner Pharmacaps Inc	amantadine hydrochloride	10888-5006	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in AMANTADINE HCL?

# Of NDCs	Excipient
1	AMMONIA
3	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Amantadine HCl Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Amantadine HCl is a mature small-molecule drug with limited opportunity in conventional immediate-release products and greater commercial potential in modified-release, sprinkle, liquid, geriatric, and abuse-deterrent formats. The principal branded opportunity is extended-release amantadine for Parkinson's disease dyskinesia and "off" episodes. Gocovri, marketed by Supernus Pharmaceuticals, uses a multiparticulate extended-release design. Osmolex ER uses an extended-release tablet platform. Generic immediate-release competition is extensive, while formulation and delivery patents remain the principal barriers to premium pricing.

What products contain amantadine hydrochloride?

Amantadine hydrochloride is available in immediate-release capsules, tablets, and oral solution, as well as extended-release products.

Product	Active ingredient	Dosage form	Primary use	Commercial status
Generic amantadine HCl	Amantadine hydrochloride	Capsules, tablets, oral solution	Parkinson's disease, drug-induced extrapyramidal reactions	Generic market
Symmetrel	Amantadine hydrochloride	Capsules, tablets, syrup	Historical reference product	Legacy brand
Gocovri	Amantadine hydrochloride	Extended-release capsules	Dyskinesia in Parkinson's disease; "off" episodes	Branded, Supernus
Osmolex ER	Amantadine hydrochloride	Extended-release tablets	Parkinson's disease and drug-induced extrapyramidal reactions	Branded, Osmotica

The FDA approved Gocovri in 2017 for dyskinesia associated with Parkinson's disease and in 2021 for "off" episodes. Osmolex ER was approved in 2018. Both products target differentiated delivery rather than a new active ingredient.[1,2]

Amantadine HCl is a weakly basic, highly water-soluble salt. Its high aqueous solubility creates a formulation challenge: unmodified dosage forms can release the drug rapidly. A commercially useful excipient strategy must therefore control diffusion, dissolution, gastrointestinal residence, or dose timing.

What excipient challenges affect amantadine HCl formulations?

The key formulation issues are rapid dissolution, dose-related adverse effects, moisture sensitivity, taste, and the need for reliable release across the gastrointestinal tract.

Rapid dissolution and release control

A water-soluble active ingredient can produce rapid drug liberation from a conventional hydrophilic matrix. For once-daily therapy, formulators need one or more of the following:

• Hydrophilic gel-forming polymers such as hypromellose.
• Hydrophobic barriers such as ethylcellulose.
• Insoluble or slowly eroding matrix formers.
• Multiparticulate coating systems.
• Osmotic or membrane-controlled delivery.
• Polymer combinations that reduce the initial burst.

The preferred platform depends on the commercial target. A simple hydrophilic matrix may lower manufacturing cost, while coated pellets or beads can offer tighter release control and better dose flexibility.

Dose dumping and food effects

Extended-release products must maintain release after exposure to changes in pH, agitation, and food composition. High-solubility drugs are particularly vulnerable to accelerated release if the dosage form depends mainly on polymer swelling.

Multiparticulate systems can reduce unit-to-unit variability. They also permit capsule opening and sprinkle administration if each pellet retains its release properties after mixing with soft food. This creates a potential advantage for patients with dysphagia, a common issue in Parkinson's disease.

Taste and oral-liquid stability

Amantadine oral solution has a potential taste burden because the active is water-soluble and can remain in the oral cavity after administration. Taste masking may use:

• Ion-exchange resins.
• Polymer coatings.
• pH adjustment.
• Sweeteners and flavor systems.
• Viscosity modifiers that reduce oral contact.

Liquid formulations also require control of microbial growth, pH drift, preservative compatibility, and precipitation during storage.

Excipient tolerability

Parkinson's patients are often older and may have renal impairment, swallowing limitations, polypharmacy, or sensitivity to gastrointestinal effects. Excipient selection should minimize unnecessary lactose, sodium, sugar, alcohol, and high-osmolality components when the target population has dietary or metabolic constraints.

The excipient strategy should also account for renal dosing. Amantadine is substantially eliminated through the kidneys, and exposure increases in renal impairment. A formulation that improves adherence but cannot support dose flexibility may have limited clinical utility.[3]

What excipient platforms are most attractive for amantadine HCl?

The strongest commercial opportunities are controlled-release multiparticulates, low-cost extended-release matrices, and patient-friendly oral liquids.

Multiparticulate extended-release capsules

Gocovri demonstrates the value of a capsule filled with modified-release pellets or beads. The platform can combine:

1. Drug-loaded cores.
2. Functional polymer layers.
3. Protective seal coats.
4. Capsule fill materials.
5. Optional immediate-release or delayed-release fractions.

Potential excipients include microcrystalline cellulose, hypromellose, povidone, ethylcellulose, talc, colloidal silicon dioxide, and magnesium stearate. Exact composition and process conditions must be established through formulation development and patent review. The commercial rationale is strong because multiparticulates can support:

• Once-daily dosing.
• Reduced peak-to-trough fluctuation.
• Capsule opening for sprinkle administration.
• More consistent gastrointestinal release.
• Differentiation from generic immediate-release products.

The main weaknesses are higher manufacturing cost, coating-process complexity, and the risk that pellet architecture falls within a branded patent claim.

Hydrophilic matrix tablets

A hydrophilic matrix tablet is the lowest-cost route to extended release. Hypromellose, polyethylene oxide, or related polymers can form a gel barrier around the soluble drug. Manufacturing may use direct compression or wet granulation.

This approach is commercially attractive for a generic or authorized-generic product because it can use standard tablet equipment. It is less attractive where the reference product relies on a multiparticulate or osmotic mechanism and the applicant must demonstrate bioequivalence against a complex release profile.

Critical variables include:

• Polymer viscosity grade.
• Polymer concentration.
• Tablet hardness.
• Drug-to-polymer ratio.
• Granule porosity.
• Lubricant level.
• Dissolution performance under fed and fasted conditions.

Hydrophobic matrix and coated-tablet systems

Ethylcellulose, waxes, fatty alcohols, and insoluble polymers can slow water penetration. These systems may provide more robust release at high drug solubility than a single low-viscosity hydrophilic polymer.

The main risk is an incomplete release profile. Excessive hydrophobicity can leave residual drug in the dosage form, while insufficient barrier strength can create rapid release after tablet erosion.

Osmotic delivery

An osmotic system can provide a reproducible release rate by using a semipermeable membrane, osmogen, and controlled delivery orifice. The approach can reduce sensitivity to gastrointestinal conditions but increases manufacturing and device complexity.

Osmotic systems are more defensible commercially when they produce a clinically meaningful profile, such as overnight coverage or reduced morning dosing burden. They are less attractive for low-price generic competition because of equipment, scale-up, and bioequivalence costs.

Oral solutions and taste-masked liquids

An improved liquid formulation could target patients with dysphagia, pediatric or geriatric use, and caregiver administration. Commercial differentiation may come from:

• Alcohol-free composition.
• Sugar-free composition.
• Preservative-free unit doses.
• Metered oral syringe compatibility.
• Improved taste masking.
• Lower sodium and lower osmolality.
• Extended in-use stability.

An oral solution is easier to develop than an extended-release product, but it is also easier to copy. Protection is more likely to come from formulation patents, packaging patents, trade dress, and manufacturing efficiency than from broad active-ingredient claims.

What patents protect amantadine HCl products?

The mature amantadine molecule has limited composition-of-matter protection. Commercial patent value is concentrated in release technology, dosage form architecture, dosing regimens, and treatment methods.

Patent category	Relevance to amantadine HCl	Commercial impact
Active ingredient	Largely expired for amantadine HCl	Does not block generic entry
Immediate-release composition	Generally weak or expired	Low barrier
Extended-release formulation	Core protection for Gocovri and Osmolex ER	Can delay or complicate generic entry
Multiparticulate capsule	Relevant to pellet loading, coatings, and release profiles	High value if claims are difficult to design around
Method of use	Dyskinesia and "off" episodes	May support litigation or carve-out strategies
Manufacturing process	Coating, granulation, membrane formation, and release control	Can create non-public know-how barriers
Packaging and administration	Sprinkle or capsule-opening instructions	Secondary differentiation

Gocovri's patent estate has included U.S. patents directed to extended-release amantadine compositions and methods. Public patent databases and FDA Orange Book records identify patents associated with the product, including patents with expiration dates extending into the 2030s.[4,5] The exact enforceable scope depends on claim construction, patent-term adjustment, terminal disclaimers, maintenance fees, and litigation outcomes.

Osmolex ER has a separate patent position associated with its extended-release delivery platform. Because the product uses a different commercial sponsor and dosage-form strategy, a competitor must analyze each product independently rather than treating all extended-release amantadine claims as interchangeable.

When does amantadine lose exclusivity?

Immediate-release amantadine has already lost practical market exclusivity. Generic capsules, tablets, and oral solution are available through multiple manufacturers.

The branded extended-release products have a later and more complicated exclusivity profile.

Milestone	Gocovri	Osmolex ER
FDA approval	2017	2018
Active ingredient new chemical entity exclusivity	No	No
Likely clinical-investigation exclusivity	Three years from approval for qualifying indications	Three years from approval for qualifying indications
Main protection today	Formulation, method-of-use, and listed patents	Formulation, method-of-use, and listed patents
Generic entry pathway	ANDA with Paragraph IV or later filing	ANDA with Paragraph IV or later filing
Practical patent horizon	Selected patents extend into the 2030s	Depends on product-specific listed patents and litigation

The absence of NCE exclusivity follows from amantadine's prior approval and long commercial history. Three-year exclusivity can apply to new clinical investigations supporting a new formulation or indication, but it does not create active-ingredient exclusivity.[1,2]

What is the Orange Book status of Gocovri and Osmolex ER?

Gocovri and Osmolex ER are prescription drug products subject to FDA-approved labeling and Orange Book listing analysis. The Orange Book records patents submitted by sponsors for approved products, but listing status does not by itself establish that every patent claim will survive litigation.[5]

For an ANDA applicant, the key questions are:

• Which patents are listed for the specific strength and dosage form?
• Are the patents formulation, method-of-use, or process patents?
• Is a Paragraph IV certification available?
• Can the applicant use a section viii statement to omit a patented indication?
• Does the product label include the protected Parkinson's indication?
• Is the proposed product bioequivalent to the reference listed drug?
• Does a 30-month stay arise from timely patent litigation?

A generic applicant may seek approval for an indication that avoids a patented use, but the product label, promotional conduct, and distribution strategy must remain consistent with the carve-out. This is particularly important for amantadine because the same active ingredient is used across Parkinson's disease, dyskinesia, "off" episodes, and drug-induced extrapyramidal reactions.

Which companies are challenging amantadine patents?

Generic amantadine manufacturers already compete in the immediate-release market. The commercially significant challenge would target Gocovri or Osmolex ER through an ANDA and Paragraph IV certification.

Publicly available market information does not establish a single dominant generic challenger for all extended-release amantadine products. The competitive field is likely to include:

• Established generic manufacturers with controlled-release capabilities.
• Specialty generic companies focused on complex oral products.
• Contract development and manufacturing organizations with pellet-coating expertise.
• Branded companies seeking authorized-generic or licensing opportunities.

A Paragraph IV filing does not guarantee market entry. Outcomes depend on patent litigation, settlement terms, FDA approval timing, pediatric exclusivity, court findings, and the applicant's ability to demonstrate bioequivalence.

What litigation and settlement risks affect amantadine?

Patent risk is concentrated in three areas.

Formulation litigation

A branded sponsor may assert claims covering polymer ratios, pellet coatings, release kinetics, capsule contents, or dissolution profiles. These claims can be difficult to evaluate from the public label because critical process parameters may not be disclosed.

Method-of-use litigation

A sponsor may assert patents covering treatment of dyskinesia or "off" episodes. An ANDA applicant may respond with a Paragraph IV challenge or a section viii carve-out. The commercial value of a method patent depends on how much of the market uses the patented indication and whether the generic label can omit it.

Settlement agreements

A settlement may establish an agreed generic launch date, authorized-generic terms, licensing rights, or restrictions on dosage strengths. FTC review and antitrust scrutiny remain relevant for pharmaceutical patent settlements.[6]

No biosimilar pathway applies. Amantadine HCl is a chemically synthesized small molecule, so competitors use the ANDA framework rather than the biosimilar pathway under section 351(k) of the Public Health Service Act.

How strong is the patent estate for amantadine HCl?

The overall patent estate is weak for immediate-release amantadine and materially stronger for complex extended-release products.

Product segment	Patent strength	Generic risk	Pricing power
Immediate-release capsule	Low	High	Low
Immediate-release tablet	Low	High	Low
Oral solution	Low to moderate	Moderate to high	Low
Hydrophilic ER tablet	Moderate	Moderate	Moderate
Multiparticulate ER capsule	Moderate to strong	Moderate	High
Sprinkle-compatible ER product	Moderate to strong	Lower if protected by claims and data	High
Osmotic ER system	Moderate to strong	Moderate	Moderate to high

The strongest defensible position combines formulation claims with clinical differentiation. A release profile alone is less valuable if it does not improve adherence, tolerability, morning function, nighttime control, or dosing convenience.

What commercial opportunities exist for amantadine excipients?

Generic extended-release products

A lower-cost extended-release product could capture patients currently using branded Gocovri or Osmolex ER. The opportunity depends on successful bioequivalence, patent clearance, and manufacturing scale.

The most efficient development path is likely a formulation that uses established excipients and standard coating equipment. A product that requires novel excipients or a new delivery device would face greater regulatory and supply-chain risk.

Sprinkle formulations

A capsule that can be opened and sprinkled on soft food could target Parkinson's patients with swallowing difficulty. This requires evidence that:

• Pellets remain intact.
• The dose is uniformly delivered.
• Food does not alter release.
• The product is not crushed or chewed.
• The administration instructions are clear.

Sprinkle functionality can support a differentiated label and a higher price than a conventional capsule.

Geriatric and renal-dose presentations

Amantadine dosing is clinically sensitive to renal function. Commercial opportunities include lower-strength tablets, scored tablets, unit-dose liquids, and packaging that reduces medication errors. A low-strength presentation can support titration and safer prescribing in older patients.

Taste-masked oral solution

A stable, alcohol-free, sugar-free liquid with improved palatability could compete in long-term-care, home-care, and dysphagia markets. Ready-to-use unit-dose packaging could reduce caregiver errors and improve hygiene.

Combination and adherence products

Combination products involving amantadine would face clinical and regulatory complexity, but adherence-oriented packaging has lower risk. Calendar packs, blister packaging, dose reminders, and coordinated morning or evening dosing may support specialty-pharmacy distribution.

Contract manufacturing and excipient supply

Suppliers with expertise in fluid-bed coating, multiparticulate layering, functional polymer systems, and controlled-release dissolution testing can sell development and commercial manufacturing services. The most valuable capabilities are process reproducibility and scale-up, not ownership of a common excipient.

How does amantadine compare with competing Parkinson's formulations?

Attribute	Immediate-release amantadine	Gocovri	Osmolex ER
Dosing profile	Shorter duration	Once-daily extended release	Extended release
Main commercial value	Low cost	Dyskinesia and "off" episode targeting	Convenience and extended exposure
Dosage form	Capsule, tablet, solution	Extended-release capsule	Extended-release tablet
Excipient complexity	Low	High	Moderate to high
Generic competition	Established	Limited relative to IR	Limited relative to IR
Patent value	Low	Formulation and use patents	Formulation and use patents
Patient convenience	Variable	High for appropriate patients	High for appropriate patients

The branded products compete less directly with generic immediate-release products than their price difference suggests. Their commercial proposition is based on pharmacokinetic control, indication-specific clinical evidence, and reduced dosing frequency.

What regulatory strategy applies to new amantadine formulations?

A reformulated product generally requires an FDA 505(b)(2) application if it relies partly on FDA findings for an existing amantadine product while introducing a new dosage form, release mechanism, strength, or route. A true generic version of an approved reference extended-release product would normally use an ANDA.

Key development requirements include:

• Comparative dissolution under multiple pH conditions.
• Fed and fasted pharmacokinetic studies.
• Dose proportionality assessment.
• Food-effect evaluation.
• Alcohol-dose-dumping assessment where relevant.
• Stability under ICH conditions.
• Extractables and leachables evaluation for coated systems.
• Human factors work for sprinkle or liquid administration.
• Renal impairment considerations in labeling.

A 505(b)(2) product may obtain method-of-use or formulation exclusivity, but the active ingredient itself does not provide new chemical entity protection.

Key Takeaways

• Immediate-release amantadine HCl is a low-margin generic market with limited excipient differentiation.
• The highest-value opportunity is extended-release delivery, particularly multiparticulate capsules and sprinkle-compatible systems.
• Gocovri and Osmolex ER rely on formulation and use differentiation rather than active-ingredient exclusivity.
• High amantadine solubility makes release control, dose dumping, and food-effect testing central development issues.
• An oral solution can target dysphagia and geriatric care, but taste, stability, and copyability constrain pricing power.
• No biosimilar pathway applies because amantadine HCl is a small-molecule drug.
• Generic entry into branded extended-release products is governed by Orange Book patents, Paragraph IV certifications, bioequivalence, litigation, and possible settlement terms.
• The strongest commercial strategy combines a differentiated dosage form, renal-dose flexibility, patient-friendly administration, and a patent position covering formulation architecture and use.

FAQs

Can amantadine HCl be formulated as a sustained-release liquid?

Yes. A sustained-release liquid could use ion-exchange resins, coated microparticles, or suspended multiparticulates. The main challenges are dose uniformity, sedimentation, microbial stability, taste masking, and proof that the suspension remains homogeneous during administration.

Which polymers are most suitable for extended-release amantadine?

Hypromellose and polyethylene oxide are common hydrophilic matrix candidates. Ethylcellulose and related water-insoluble polymers are useful for coated pellets and hydrophobic matrices. The optimal polymer depends on the target dissolution profile, manufacturing process, and patent clearance.

Is an amantadine HCl sprinkle capsule commercially viable?

Yes. A sprinkle capsule could address swallowing difficulty in Parkinson's disease. The product must demonstrate that opening the capsule does not alter dose delivery, pellet integrity, release rate, or food compatibility.

Does amantadine HCl require a biosimilar application?

No. Amantadine HCl is a small-molecule active ingredient. A generic applicant normally uses an ANDA, while a new formulation or new delivery system may use a 505(b)(2) application.

What is the most defensible amantadine formulation business?

A once-daily, sprinkle-compatible extended-release multiparticulate capsule with lower strengths and strong renal-dose flexibility offers the best combination of clinical utility, excipient differentiation, and commercial defensibility.

References

1. U.S. Food and Drug Administration. (2017). Gocovri (amantadine) extended-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2018). Osmolex ER (amantadine hydrochloride) extended-release tablets: Prescribing information.
3. U.S. Food and Drug Administration. (2020). Symmetrel (amantadine hydrochloride) prescribing information.
4. United States Patent and Trademark Office. (2024). Patent Center and Patent Assignment Search.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. Federal Trade Commission. (2023). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.